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Abstract
This is a case report of adrenomyeloneuropathy (AMN), the adult variant of adrenoleukodystryphy (ALD). The
diagnoses in the patient, aged 34, was confirmed via increased serum very long chain fatty acid concentration
(VLCFA). Treatment started with the cholesterol lowering drug, atorvastatin, followed by add-on therapy with
Lorenzo’s oil (LO) and finally supplementation with docosahexaenoic acid (DHA). The magnetic resonance imaging
(MRI) scan of the AMN patient before DHA treatment, already showed abnormal white matter in the brain.
Although the MRI showed no neurological improvement after 6 months of DHA treatment, no selective
progression of demyelination was detected in the AMN patient. Contrary to what was expected, LO failed to
sustain or normalize the VLCFA levels or improve clinical symptoms. It was however, shown that DHA
supplementation in addition to LO, increased DHA levels in both plasma and red blood cells (RBC). Additionally,
the study showed evidence that the elongase activity in the elongation of eicosapentaenoic acid (EPA) to
docosapentaenoic acid (DPA) might have been significantly compromised, due to the increased DHA levels.
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Introduction
Adrenomyeloneuropathy (AMN), one of the variants of
X-linked adrenoleukodystrophy (X-ALD), is an inherited
genetic disorder, classified as a single peroxisomal
enzyme disorder that affects the peroxisomal b-oxida-
tion pathway. Cerebral demyelination may develop in
males and is confirmed via clinical and MRI evidence of
inflammatory brain involvement [1]. Biochemically, this
disease is associated with the abnormal accumulation of
saturated, very long chain fatty acids (VLCFA), espe-
cially C24:0 and C26:0 [2].
Although different therapies have been employed to
treat X-ALD, there is currently no cure. Recent articles
suggest cholesterol management as a potential treat-
ment. In X-ALD patients, accumulation of VLCFA is
mainly in the form of cholesterol ester fractions in ALD
tissues, particularly the brain [3]. It was demonstrated in
a previous study that the HMG-CoA reductase inhibitor,
lovastatin, caused a reduction in the VLCFA plasma
l e v e l so fX - A L Dp a t i e n t s[ 4 ] .T h e r e f o r e ,i ti sc o n t e m -
plated that an interaction between cholesterol and
VLCFA metabolism does exist [5]. However, the exact
mechanism is still unknown. Another alternative therapy
consists of Lorenzo’s oil (LO) (mixture of oleic and
erucic acid) in combination with a diet low in VLCFA.
Although VLCFA plasma levels of ALD patients were
lowered within 4 weeks after treatment with LO [6], no
improvement of neurological symptoms has been
reported in the literature [7]. Elevated levels of erucic
and nervonic acids in plasma, as well as a reduction in
docosahexaenoic acid (DHA) and eicosapentanoic acid
(EPA) had been observed in patients treated with LO
[8]. Results from another study also indicated a decrease
in DHA plasma levels after treating AMN patients with
LO [9], leading to speculation that erucic acid could
have an effect on the metabolism of DHA. The mechan-
ism of action of Lorenzo’s oil could be attributed to
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fatty acids in the VLCFA synthesis pathway, resulting in
a reduction of the VLCFA concentrations [8]. Competi-
tion for the elongation enzyme in the DHA biosynthesis
p a t h w a yb ye r u c i ca c i dc o u l db eap o s s i b l em e c h a n i s m
for decreased DHA levels observed with Lorenzo’so i l
treatment. In order to normalize the essential fatty acid
depletion, supplementation with DHA is usually recom-
mended [8].
The aim of this study, was to establish if supplementa-
tion with DHA in addition to treatment with LO, might
increase plasma and red blood cell (RBC) DHA levels
and improve clinical symptoms in a patient diagnosed
with X-ALD (phenotype AMN).
Clinical Report
A 28-year-old male patient started to complain about
finding it difficult to walk as well as of bladder dysfunc-
tion. Magnetic Resonance Imaging (MRI) confirmed the
diagnosis of a degenerative neurological disorder. At age
34, the diagnoses of ALD was confirmed at the labora-
tory for Inherited Metabolic Defects, School for Bio-
chemistry, North-West University (Potchefstroom
Campus), South Africa, as well as at the laboratory for
Genetische Metabole Ziekten in Amsterdam, The Neth-
erlands, via increased plasma levels of VLCFA (C26:0
and C24:0) as well as high ratios of C24:0/C22:0 and
C26:0/C22:0.
The clinical picture was typical of the AMN pheno-
type. The following symptoms were present during phy-
sical examination: spastic paraparesis, ataxia, variable
episodes of hypertonia and spasms, impotence (possibly
related to the spinal cord involvement), intermittent
behavioural changes and bladder dysfunction.
Approximately one year after diagnosis, brain involve-
ment was again assessed by MRI. Even though abnormal
white matter was clearly observed, the patient was diag-
nosed with the AMN phenotype. At that time, the neu-
rological progression of the patient was also rated using
the ALD-Disability Rating Scale [10]. On that occasion,
the patient was rated at number two, indicating that he
did require some interventions. No adrenal insufficiency
was noted with an ACTH stimulation test.
Treatment with the cholesterol lowering drug, atorvas-
tatin (10 mg/day), and L-carnitine (2g/day) started
immediately after diagnosis. After three months, LO (10
ml/day) was added to the treatment to effect inhibition
of VLCFA elongation. This treatment continued for
seven months (March 2008 to September 2008) and was
then supplemented with DHA (600 mg/day in divided
doses) for eight months. The DHA supplementation
consisted of a mixture of medium chain triglyceride oil
(MCT), fish oil (40% DHA, 5% EPA) and vitamin E as
an antioxidant.
T h eV L C F A ,p h y t a n i ca n dp r i s t a n i ca c i dc o n t e n ti n
plasma, during all the treatment phases (cholesterol low-
ering, LO, DHA) and the polyunsaturated fatty acid
(PUFA) content in plasma during LO treatment were
determined. The effect of the DHA treatment was estab-
lished by determining PUFA in both plasma and RBC
and a clinical evaluation was carried out using an ALD-
Disability Rating Scale and an MRI scan. The latter eva-
luations were done before and after DHA therapy
started. Plasma concentrations of oleic and erucic acid
were measured every month to corroborate compliance
to the dietary treatment.
Analytical Procedures
This case study was approved by the Ethics Committee
of the North-West University (Potchefstroom Campus)
(application number NWU-0038-08-S5). Informed con-
sent was obtained from the patient for this case study.
Blood collection
The AMN patient fasted for 10 to 14 hours prior to the
collection of blood samples. For analysis of the PUFA,
blood samples were collected in vacutainers containing
EDTA.
The method described by Evans and co-workers [11],
was used for separating plasma and RBC and samples
were stored at -80°C until analysis. Plasma and RBC
were obtained from age matched healthy human
subjects.
Analysis of saturated VLCFAs, in plasma
A modified method from Vreken and co-workers [12]
was used for sample preparation and determination of
VLCFAs. The samples were analyzed by GC/MS (Hew-
lett-Packard model 6890/5973 GC-MS system),
equipped with a 120-0132 DB-1ms capillary column (30
m × 0.25 mm i.d. × 0.25 μmf i l mt h i c k n e s s )( A g i l e n t
Technologies, Chemetrix, Midrand, South Africa).
Samples were injected into the GC/MS system with
splitless mode and the carrier gas was helium. The elec-
tron impact ionization was applied at 0.7 eV and the
mass spectrum with single ion monitoring (SIM) mode,
was used to monitor the characteristic [M-57]
+ ions
[12]. The oven temperature was programmed to start at
a temperature of 60°C for 1 minute. The temperature
was then increased to 240°C (30°C/min), followed by an
increase to 270°C (10°C/min) and finally by an increase
to 300°C (4°C/min) where it was maintained for 3 min-
utes. HP-chemstation software was used to quantify the
raw data obtained from the GC/MS.
Analysis of PUFA in RBC
For the sample preparation of the RBC a modified ver-
sion of the procedures by Takemoto and co-workers [2]
and by Blau and co-workers [13] were used. The con-
centrations of the fatty acid methyl esters (FAME) in
the RBC samples were analyzed by GC/MS (Agilent
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gies 5973 MS system) equipped with a capillary column
(Agilent 19091S-433). The injector (7683 B Series) tem-
perature was set at 250°C and helium was used as car-
rier gas. The RBC samples were injected into the GC/
MS system with splitless mode. The oven temperature
was initially set at 50°C and was increased to 190°C (30°
C/min), then to 220°C (3°C/min), and finally to 230°C
(6°C/min) and maintained for 24 minutes.
Identification of the PUFA peaks was carried out via
AMDIS, an Automated Mass Spectral Deconvolution
and Identification System. The mass spectra of the fatty
acids were obtained from the National Institute of Stan-
dards and Technology (NIST) library.
Analysis of PUFA in plasma with TLC
The methods of Takemoto and colleagues [2] and Blau
and co-workers [13], were modified for sample prepara-
tion. Purification of the samples was achieved by adapt-
ing the thin-layer chromatography method by Smuts
and Tichelaar [14] for methyl esters. The samples were
analyzed with a GC/MS (Agilent Technologies 6890N
GC system and Agilent Technologies 5973 MS system)
equipped with a capillary column (J&W 122-2361). The
injector (7683 B Series) temperature was set at 250°C
and helium was used as carrier gas.
The plasma samples were injected into the GC/MS
system with split mode. The split ratio was set at 5:1
with a flow of 4.4 ml/min. The oven temperature was
initially set to 160°C and increased to 220°C (3°C/min)
where it was maintained for 15 minutes. Samples were
quantified with Chemstation Enhanced Data analysis
software (version D.01.XX) using unique single ions and
calibration curves for each FAME.
Results and discussion
The results showed that both the C24:0/C22:0 and
C26:0/C22:0 plasma ratios were reduced within one
month of starting therapy with atorvastatin and L-carni-
tine, compared to the pre-treatment value and that
these ratios remained lowered during the first three
months of treatment (Figure 1a and 1b). Unfortunately,
plasma C26:0 concentrations increased slightly (Figure
1c). Currently, the exact mechanism of how cholesterol
lowering drugs reduces plasma levels of VLCFA in X-
ALD patients is unknown [4]. It has been suggested that
the effect of lovastatin on plasma VLCFA may rather be
attributed to its effect on the cholesterol synthesis than
to a direct effect on the VLCFA metabolism [15]. Since
no clinical improvement was noted, LO was added to
the treatment regime.
Lorenzo’s oil decreased plasma VLCFA ratios C24:0/
C22:0 and C26:0/C22:0 after one month of treatment,
however, over a period of six months after therapy
started, these ratios increased to values higher than
before LO treatment began (Figure 1a and 1b). Plasma
C26:0 concentrations sharply decreased after one month
of LO treatment, but levels then started to increase
(Figure 1c). Decreased plasma DHA levels (Figure 2),
below normal control values, were noted for the entire
period in which LO, atorvastatin and L-carnitine were
administered (March 2008 to September 2008). Once
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Figure 1 VLCFA plasma levels of the AMN patient: where (a)
depicts the ratio C24:0/C22:0; (b) depicts the ratio C26:0/C22:0
and (c) depticts the concentration C26:0. The symbols represent:
black diamond-one month after artorvastatin and L-carnitine started
(November 2007); black triangle-one month after Lorenzo’s oil
started (March 2008) and the black sircle-one month after DHA
started (October 2008). The grey dashed line indicates the threshold
for the analysed data to be regarded as normal subject values.
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attributed to LO treatment, which is in accordance to
the study of Moser and coworkers [16] where they
found the severe reduction in ω-3 and ω-6 fatty acids,
including DHA during LO treatment in the absence of
ω-3 and ω-6 supplementation. In this case study, LO
initially decreased plasma VLCFA levels and ratios, but
failed to sustain or normalize VLCFA levels and to
improve clinical symptoms. We found raised concentra-
tions of oleic and erucic acid in the plasma of the
patient that corroborated the adherence to the therapy.
DHA supplementation had no effect on plasma C24:0/
C22:0 ratios for the entire therapeutic period (Figure
1a). An unexplained increase in C26:0/C22:0 ratio and
C26:0 concentration, one month after DHA therapy
started, was noticed, which gradually decreased to nor-
mal values in the following three months (November’08
to January’09). Thereafter these values increased, and
remained at these higher levels during the DHA treat-
ment phase without any further increase (Figure 1b and
1c). Significantly, supplementation with DHA increased
plasma and RBC DHA values (see Figure 2 and 3a)
within a few weeks after the initiation of treatment and
remained above the mean DHA levels of the control
samples collected for a period of six and three months.
Hereafter, both plasma and RBC DHA values returned
to the mean DHA levels of the control samples.
One month after DHA supplementation started, a
sharp increase in RBC EPA levels (Figure 3b) was noted,
followed by a gradual increase for the remainder of
DHA treatment. Coinciding with EPA increasing, the
RBC DPA/EPA ratio (Figure 3c) showed a sharp
decrease, gradually declining for the remainder of DHA
treatment. One mechanism that might account for
this decreased DPA/EPA ratio, involves a regulatory
mechanism in which the high DHA levels exert a nega-
tive feedback mechanism on the elongase enzyme
responsible for the elongation of EPA to DPA (Figure
4). The decreased activity of this elongase enzyme sub-
sequently leads to higher EPA levels, thus explaining the
increased EPA levels in the patient after DHA supple-
mentation. Supporting these findings is a metabolic
Figure 2 DHA plasma analysis of the AMN patient where the
concentration of DHA is depicted for the period February 2008
to June 2009. The symbols represent: black triangle-one month
after Lorenzo’s oil started (March 2008); and the black sircle-one
month after DHA started (October 2008). The grey dashed line
indicates the average of control samples collected.
 
 
Figure 3 Omega 3 PUFA RBC analysis of the AMN patient
where (a) depicts the concentrations of EPA; (b) depicts the
concentrations of DHA and (c) the ratio of DPA/EPA for the
period of September 2008 to April 2009. The black circle,
(October 2008), represents one month after DHA supplementation
was started. The grey dashed line indicates the average value of
control samples collected.
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elongase activities might be altered with long-chain
polyunsatured fatty acid feeding. Mice were fed control
diets and fish oil enriched with DHA and EPA. The
ratios of C22:4 n-6/C20:4 n-6 and C22:5 n-3/C20:5 n-3
were all reduced by the fish oil feeding. The current
study also showed a decrease C22:4 n-6/C20:4 n-6 ratio
in both plasma and RBC, confirming elongation inhibi-
tion (data not shown).
Subsequently, the increased DHA and EPA levels could
also lead to an anti-inflammatory effect. DHA and EPA
competitively inhibit the oxygenation of arachidonic acid
(C20:4 n-6; AA) [18], thereby decreasing production of
AA-derived eicosanoids. DHA reduces C20:4 n-6 bio-
synthesis via the inhibition of Δ5o rΔ6 desaturase [19],
whereas EPA displaces C20:4 n-6 from phospholipids.
The present study also confirmed the inhibition of Δ6
desaturase, as is indicated by the decreased plasma ratio,
C18:3 n-6/C18:2 n-6, after one month of DHA supple-
mentation (data not shown).
The MRI scans illustrate that the AMN patient
already showed abnormal white matter lesions, typical
of ALD, at the onset of this study. Abnormal white mat-
ter was shown on the white matter MRI series, grey
matter MRI series, the FLAIR study and the T2
weighted study (Figure 5a and 5b). No definite abnormal
white matter progression could be identified on either
the FLAIR or the T2 weighted studies for September
2008 and March 2009, during treatment with LO and
DHA supplementation. Although the MRI scans before
and after DHA supplementation showed no neurological
improvement after six months of DHA treatment, no
selective progression of demyelination was detected.
This stabilization was further supported by the ALD-
Disability Rating Scale, that remained unchanged (at
number two) for the DHA treatment phase. Since the
patient had been diagnosed in October 2007 and had
already been showing symptoms when DHA supplemen-
tation started a year later, it could be argued that DHA
prevented further neurological progression although no
improvement was evident.
In conclusion: it was confirmed that supplementation
with DHA, in addition to LO and treatment with a cho-
lesterol lowering drug, atorvastatin, increased DHA
levels in plasma and RBC of the AMN patient. These
Figure 4 Schematic of the possible negative feedback
mechanism by DHA through inhibition of the elongase
between EPA and DPA. Abreviations: ALA = a-Linoleic acid, EPA =
eicosapentaenoic acid DPA = docosapentaenoic acid and DHA =
docosahexaenoic acid.
Figure 5 Brain MRI scans of the AMN patient: T2 weighted one month before DHA treatment began (September 2008) (left) and T2
weighted six months after DHA treatment began (March 2009) (right).
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Page 5 of 6increased DHA levels may exert a neuro-protective
effect by a negative feedback mechanism, leading to an
increase in EPA. In turn, EPA and DHA are incorpo-
rated into inflammatory cell phospholipids, partly at the
expense of AA, exerting an anti-inflammatory effect
[20]. Sing and Pujol also suggested that treatment strate-
gies should be developed for the inflammatory, meta-
bolic and oxidative stress disease aspects of X-ALD [21].
Supplementation with DHA, is therefore strongly
recommended in patients with X-ALD patients, due to
the important role of DHA in brain development and
myelination and the feedback mechanism which may
cause a neuro-protective and anti-inflammatory effect.
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